Therapeutic Goods Regulations (Amendment)

Overview

The Therapeutic Goods Act 1966 was enacted to regulate the importation, supply, and use of therapeutic goods in Australia, ensuring they are safe and of high quality. To address the evolving landscape of therapeutic substances, particularly the complexities involved in the regulation of monoclonal antibodies, the Therapeutic Goods Regulations were amended through Statutory Rules 1985 No. 297. Issued under the authority of the Minister for Health, these rules establish the Monoclonal Antibody Committee to advise on the quality, safety, and efficacy of monoclonal antibodies. This committee is composed of experts in relevant scientific fields, appointed by the Minister, and its formation aims to ensure that the potential hazards associated with monoclonal antibodies are effectively managed, thereby protecting public health.

Scope and Application

The Therapeutic Goods Regulations, established under the Therapeutic Goods Act 1966, encompass the creation of committees to advise the Minister for Health on various aspects of therapeutic goods, including the importation and regulation of therapeutic substances. Specifically, the Monoclonal Antibody Committee, established under these regulations, is tasked with providing expert advice on the quality, safety, and efficacy of monoclonal antibodies and related products for therapeutic use. This committee comprises a Chairman, an officer from the Department of Health, a person with scientific expertise in monoclonal antibody manufacture, and four other experts in relevant scientific fields. The committee operates under the general provisions set forth in the existing regulations, including those governing the tenure of office, committee functions in case of a vacancy, and allowances for members. These rules apply nationally within Australia and came into effect on the date of their notification in the Commonwealth of Australia Gazette, thereby ensuring comprehensive and expert oversight of monoclonal antibodies in the therapeutic context.

Key Provisions

The Therapeutic Goods Act 1966 (section 30(a)) allows for the establishment of committees to advise the Minister on matters relating to the importation of therapeutic substances into Australia, among other things. The Therapeutic Goods Regulations provide for the formation of various committees, with Part III specifically detailing general provisions applicable to these committees. In light of developments in the field of monoclonal antibodies, the Statutory Rules establish a dedicated committee to advise on the regulation of these substances' quality, safety, and efficacy. This new committee, the Monoclonal Antibody Committee (section 19A(1)), is mandated to provide expert advice to the Minister. The composition of the Monoclonal Antibody Committee (section 19A(2)) includes the Chairman of the Australian Drug Evaluation Committee or a delegate, an officer from the Department of Health or a delegate, one expert in the manufacture of monoclonal antibodies, and four additional experts in fields such as biochemistry, molecular biology, immunology, protein chemistry, and clinical medicine. The Minister has the discretion to appoint a Chairman from among the members (section 19A(3)), and the committee's primary function is to advise on matters affecting the quality, efficacy, and safety of monoclonal antibodies and related products intended for therapeutic use. The Statutory Rules also amend sub-regulation 23(2) of the Therapeutic Goods Regulations (Regulation 2) by adding a provision that a quorum for the Monoclonal Antibody Committee consists of four members. The Rules further clarify that the committee will operate under the general provisions of the existing Regulations, including provisions regarding the tenure of office, procedures for filling vacancies, and entitlements to sitting fees and travel allowances. The Statutory Rules took effect on the date of their notification in the Commonwealth of Australia Gazette. The obligations and requirements imposed by the Therapeutic Goods Regulations on the parties and entities governed by the Act are extensive. The Regulations mandate the composition and functions of the Monoclonal Antibody Committee, ensuring that it comprises experts in relevant fields and that it advises the Minister on critical matters related to the therapeutic use of monoclonal antibodies. These obligations extend to the appointment and tenure of committee members, as well as the establishment of a quorum for committee meetings. Furthermore, the Regulations outline the process for filling vacancies and the entitlement to fees and allowances for committee members, ensuring that the committee can function effectively and independently. Breach of the provisions outlined in the Therapeutic Goods Regulations can result in significant consequences. While the Statutory Rules themselves do not specify particular offences or penalties, the broader Therapeutic Goods Act and associated Regulations do. The Act provides for both civil and criminal penalties for breaches, which can include fines and imprisonment. For example, under section 30 of the Act, a person who contravenes a provision of the Act or the Regulations may be subject to a fine of up to $55,000 for an individual offence and $275,000 for a corporate offence. In more serious cases, the Act allows for imprisonment for up to two years for an individual offence and five years for a corporate offence. These penalties underscore the importance of compliance with the Act and Regulations in ensuring the quality, safety, and efficacy of therapeutic goods in Australia.